Adjuvant treatment in node-negative, postmenopausal breast cancer

Cancer Invest. 2001;19(7):706-22. doi: 10.1081/cnv-100106146.
No abstract available

Publication types

  • Review

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Breast Neoplasms / surgery
  • Chemotherapy, Adjuvant*
  • Cyclophosphamide / administration & dosage
  • Female
  • Fluorouracil / administration & dosage
  • Humans
  • Lymphatic Metastasis*
  • Methotrexate / administration & dosage
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Staging
  • Patient Care Planning
  • Postmenopause
  • Randomized Controlled Trials as Topic
  • Receptors, Estrogen / analysis
  • Receptors, Progesterone / analysis
  • Risk Factors
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • Cyclophosphamide
  • Fluorouracil
  • Methotrexate

Supplementary concepts

  • CMF regimen